FREE SHIPPING over $40
OVER 10000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Vaccine2006; 24(17); 3636-3645; doi: 10.1016/j.vaccine.2006.01.062

Comparison of the efficacy of inactivated combination and modified-live virus vaccines against challenge infection with neuropathogenic equine herpesvirus type 1 (EHV-1).

Abstract: Equine herpesvirus type 1 (EHV-1) is a ubiquitous alphaherpesvirus of horses which causes rhinopneumonitis, abortion and myeloencephalopathy. To test the efficacy of commercial vaccines in protection against neurological EHV-1 challenge, groups of five horses were immunized with modified-live virus or an inactivated vaccine, or received placebo. Horses were challenged by aerosol with a recent virus isolate obtained from a case of paralytic EHV-1. The duration of fever decreased significantly in the modified-live virus vaccine group. Three animals in each of the inactivate and control groups showed alterations in neurological status. When compared to the inactivated vaccine, the modified-live virus vaccine induced significantly lower virus-neutralizing antibodies over the course of the study. The modified-live virus vaccine resulted in low EHV-1-specific IgG(T)/IgGa and IgG(T)/IgGb ratios, suggesting a bias towards a cytotoxic immune response. Virus shedding from the nasopharynx was almost undetectable in the modified-live virus group, and was significantly lower when compared to that in the other groups. Normalized lymphocyte viral genome copies were similar for the three groups, although animals vaccinated with the modified-live virus vaccine were qPCR-positive on fewer days when compared to those of the other groups. Based on data from neurological signs, rectal temperatures, virus isolation from nasal swabs and immune response specificity, we concluded that protection induced by the modified-live virus vaccine is superior to that induced by the inactivated combination vaccine.
Get Full Text
Publication Date: 2006-02-13 PubMed ID: 16513225DOI: 10.1016/j.vaccine.2006.01.062Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Comparative Study
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article discusses a study comparing the effectiveness of the modified-live virus and inactivated combination vaccines in protecting horses from a neurological challenge posed by the equine herpesvirus type 1 (EHV-1). It concludes that the modified-live virus vaccine offers superior protection against EHV-1.

Research Objective and Methodology

  • The primary goal of this study was to evaluate the effectiveness of two commercial equine vaccines against equine herpesvirus type 1 (EHV-1), a common virus affecting horses that can cause rhinopneumonitis, abortion, and myeloencephalopathy.
  • To conduct this investigation, groups of five horses were immunized either with a modified-live virus vaccine, an inactivated vaccine, or were given a placebo.
  • The horses were subsequently challenged with a recent strain of the EHV-1 virus, which had been isolated from a paralytic case of EHV-1.
  • The researchers measured multiple factors, such as duration of fever, alterations in neurological status, virus-neutralizing antibodies, specific immune response, virus shedding and the presence of viral genome copies in lymphocytes.

Research Outcomes

  • The research found that the duration of fever significantly decreased in the group of horses immunized with the modified-live virus vaccine.
  • Different immune responses were noted in horses vaccinated with the two different types. The modified-live virus vaccine induced significantly lower virus-neutralizing antibodies over the course of the study, suggesting a shift towards a cytotoxic immune response.
  • The modified-live virus vaccine was found to inhibit virus shedding from the nasopharynx (almost undetectable virus shedding in this group), which was significantly lower compared to the other groups.
  • The vaccination with the modified-live virus vaccine resulted in qPCR-positive results on fewer days as compared to the other groups, indicating lower levels of viral genome copies in lymphocytes.
  • Based on observations of neurological signs, rectal temperatures, virus isolation from nasal swabs, and immune response specificity, it was concluded that the modified-live virus vaccine provides superior protection against EHV-1 compared to the inactivated combination vaccine.

Cite This Article

APA
Goodman LB, Wagner B, Flaminio MJ, Sussman KH, Metzger SM, Holland R, Osterrieder N. (2006). Comparison of the efficacy of inactivated combination and modified-live virus vaccines against challenge infection with neuropathogenic equine herpesvirus type 1 (EHV-1). Vaccine, 24(17), 3636-3645. https://doi.org/10.1016/j.vaccine.2006.01.062

Publication

Vaccine
ISSN: 0264-410X
NlmUniqueID: 8406899
Country: Netherlands
Language: English
Volume: 24
Issue: 17
Pages: 3636-3645

Researcher Affiliations

Goodman, Laura B
  • Department of Microbiology and Immunology, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA.
Wagner, Bettina
    Flaminio, M J B F
      Sussman, Karen H
        Metzger, Stephan M
          Holland, Robert
            Osterrieder, Nikolaus

              MeSH Terms

              • Animals
              • Antibodies, Viral / blood
              • Herpesviridae Infections / prevention & control
              • Herpesviridae Infections / veterinary
              • Herpesviridae Infections / virology
              • Herpesvirus 1, Equid / immunology
              • Herpesvirus 1, Equid / isolation & purification
              • Herpesvirus Vaccines / immunology
              • Horse Diseases / prevention & control
              • Horses
              • Immunoglobulin G / blood
              • Immunoglobulin G / classification
              • Nasopharynx / virology
              • Polymerase Chain Reaction
              • Respiration
              • Vaccination / veterinary
              • Vaccines, Inactivated / immunology
              • Virus Shedding

              Citations

              This article has been cited 40 times.
              1. El Brini Z, Fassi Fihri O, Paillot R, Lotfi C, Amraoui F, El Ouadi H, Dehhaoui M, Colitti B, Alyakine H, Piro M. Seroprevalence of Equine Herpesvirus 1 (EHV-1) and Equine Herpesvirus 4 (EHV-4) in the Northern Moroccan Horse Populations. Animals (Basel) 2021 Sep 29;11(10).
                doi: 10.3390/ani11102851pubmed: 34679874google scholar: lookup
              2. Vandenberghe E, Boshuizen B, Delesalle CJG, Goehring LS, Groome KA, van Maanen K, de Bruijn CM. New Insights into the Management of an EHV-1 (Equine Hospital) Outbreak. Viruses 2021 Jul 22;13(8).
                doi: 10.3390/v13081429pubmed: 34452295google scholar: lookup
              3. Sutton G, Thieulent C, Fortier C, Hue ES, Marcillaud-Pitel C, Pléau A, Deslis A, Guitton E, Paillot R, Pronost S. Identification of a New Equid Herpesvirus 1 DNA Polymerase (ORF30) Genotype with the Isolation of a C(2254)/H(752) Strain in French Horses Showing no Major Impact on the Strain Behaviour. Viruses 2020 Oct 13;12(10).
                doi: 10.3390/v12101160pubmed: 33066315google scholar: lookup
              4. Attili AR, Colognato R, Preziuso S, Moriconi M, Valentini S, Petrini S, De Mia GM, Cuteri V. Evaluation of Three Different Vaccination Protocols against EHV1/EHV4 Infection in Mares: Double Blind, Randomized Clinical Trial. Vaccines (Basel) 2020 Jun 1;8(2).
                doi: 10.3390/vaccines8020268pubmed: 32492841google scholar: lookup
              5. Prutton JSW, Barnum S, Pusterla N. Evaluation of safety, humoral immune response and faecal shedding in horses inoculated with a modified-live bovine coronavirus vaccination. Equine Vet Educ 2020 Aug;32(Suppl 11):33-36.
                doi: 10.1111/eve.13175pubmed: 32427191google scholar: lookup
              6. Dunuwille WMB, YousefiMashouf N, Balasuriya UBR, Pusterla N, Bailey E. Genome-wide association study for host genetic factors associated with equine herpesvirus type-1 induced myeloencephalopathy. Equine Vet J 2020 Nov;52(6):794-798.
                doi: 10.1111/evj.13261pubmed: 32153055google scholar: lookup
              7. Lecollinet S, Pronost S, Coulpier M, Beck C, Gonzalez G, Leblond A, Tritz P. Viral Equine Encephalitis, a Growing Threat to the Horse Population in Europe?. Viruses 2019 Dec 24;12(1).
                doi: 10.3390/v12010023pubmed: 31878129google scholar: lookup
              8. Yan L, Toohey-Kurth KL, Crossley BM, Bai J, Glaser AL, Tallmadge RL, Goodman LB. Inhibition monitoring in veterinary molecular testing. J Vet Diagn Invest 2020 Nov;32(6):758-766.
                doi: 10.1177/1040638719889315pubmed: 31735123google scholar: lookup
              9. Schnabel CL, Babasyan S, Rollins A, Freer H, Wimer CL, Perkins GA, Raza F, Osterrieder N, Wagner B. An Equine Herpesvirus Type 1 (EHV-1) Ab4 Open Reading Frame 2 Deletion Mutant Provides Immunity and Protection from EHV-1 Infection and Disease. J Virol 2019 Nov 15;93(22).
                doi: 10.1128/JVI.01011-19pubmed: 31462575google scholar: lookup
              10. Bannai H, Tsujimura K, Nemoto M, Ohta M, Yamanaka T, Kokado H, Matsumura T. Epizootiological investigation of equine herpesvirus type 1 infection among Japanese racehorses before and after the replacement of an inactivated vaccine with a modified live vaccine. BMC Vet Res 2019 Aug 6;15(1):280.
                doi: 10.1186/s12917-019-2036-0pubmed: 31387602google scholar: lookup
              11. Azab W, Bedair S, Abdelgawad A, Eschke K, Farag GK, Abdel-Raheim A, Greenwood AD, Osterrieder N, Ali AAH. Detection of equid herpesviruses among different Arabian horse populations in Egypt. Vet Med Sci 2019 Aug;5(3):361-371.
                doi: 10.1002/vms3.176pubmed: 31149784google scholar: lookup
              12. Holz CL, Sledge DG, Kiupel M, Nelli RK, Goehring LS, Soboll Hussey G. Histopathologic Findings Following Experimental Equine Herpesvirus 1 Infection of Horses. Front Vet Sci 2019;6:59.
                doi: 10.3389/fvets.2019.00059pubmed: 30886853google scholar: lookup
              13. Rocha JN, Dangott LJ, Mwangi W, Alaniz RC, Bordin AI, Cywes-Bentley C, Lawhon SD, Pillai SD, Bray JM, Pier GB, Cohen ND. PNAG-specific equine IgG(1) mediates significantly greater opsonization and killing of Prescottella equi (formerly Rhodococcus equi) than does IgG(4/7). Vaccine 2019 Feb 21;37(9):1142-1150.
                doi: 10.1016/j.vaccine.2019.01.028pubmed: 30691984google scholar: lookup
              14. Wimer CL, Schnabel CL, Perkins G, Babasyan S, Freer H, Stout AE, Rollins A, Osterrieder N, Goodman LB, Glaser A, Wagner B. The deletion of the ORF1 and ORF71 genes reduces virulence of the neuropathogenic EHV-1 strain Ab4 without compromising host immunity in horses. PLoS One 2018;13(11):e0206679.
                doi: 10.1371/journal.pone.0206679pubmed: 30440016google scholar: lookup
              15. Schnabel CL, Wimer CL, Perkins G, Babasyan S, Freer H, Watts C, Rollins A, Osterrieder N, Wagner B. Deletion of the ORF2 gene of the neuropathogenic equine herpesvirus type 1 strain Ab4 reduces virulence while maintaining strong immunogenicity. BMC Vet Res 2018 Aug 22;14(1):245.
                doi: 10.1186/s12917-018-1563-4pubmed: 30134896google scholar: lookup
              16. Tallmadge RL, Žygelytė E, Van de Walle GR, Kristie TM, Felippe MJB. Effect of a Histone Demethylase Inhibitor on Equine Herpesvirus-1 Activity In Vitro. Front Vet Sci 2018;5:34.
                doi: 10.3389/fvets.2018.00034pubmed: 29594155google scholar: lookup
              17. Wagner B, Perkins G, Babasyan S, Freer H, Keggan A, Goodman LB, Glaser A, Torsteinsdóttir S, Svansson V, Björnsdóttir S. Neonatal Immunization with a Single IL-4/Antigen Dose Induces Increased Antibody Responses after Challenge Infection with Equine Herpesvirus Type 1 (EHV-1) at Weanling Age. PLoS One 2017;12(1):e0169072.
                doi: 10.1371/journal.pone.0169072pubmed: 28045974google scholar: lookup
              18. Gildea S, Sanchez Higgins MJ, Johnson G, Walsh C, Cullinane A. Concurrent vaccination against equine influenza and equine herpesvirus - a practical approach. Influenza Other Respir Viruses 2016 Sep;10(5):433-7.
                doi: 10.1111/irv.12396pubmed: 27169603google scholar: lookup
              19. Ortved K, Wagner B, Calcedo R, Wilson J, Schaefer D, Nixon A. Humoral and cell-mediated immune response, and growth factor synthesis after direct intraarticular injection of rAAV2-IGF-I and rAAV5-IGF-I in the equine middle carpal joint. Hum Gene Ther 2015 Mar;26(3):161-71.
                doi: 10.1089/hum.2014.050pubmed: 25705927google scholar: lookup
              20. Bannai H, Mae N, Ode H, Nemoto M, Tsujimura K, Yamanaka T, Kondo T, Matsumura T. Successful control of winter pyrexias caused by equine herpesvirus type 1 in Japanese training centers by achieving high vaccination coverage. Clin Vaccine Immunol 2014 Aug;21(8):1070-6.
                doi: 10.1128/CVI.00258-14pubmed: 24872513google scholar: lookup
              21. Goodman LB, Wimer C, Dubovi EJ, Gold C, Wagner B. Immunological correlates of vaccination and infection for equine herpesvirus 1. Clin Vaccine Immunol 2012 Feb;19(2):235-41.
                doi: 10.1128/CVI.05522-11pubmed: 22205656google scholar: lookup
              22. Soboll Hussey G, Hussey SB, Wagner B, Horohov DW, Van de Walle GR, Osterrieder N, Goehring LS, Rao S, Lunn DP. Evaluation of immune responses following infection of ponies with an EHV-1 ORF1/2 deletion mutant. Vet Res 2011 Feb 7;42(1):23.
                doi: 10.1186/1297-9716-42-23pubmed: 21314906google scholar: lookup
              23. Brosnahan MM, Damiani A, van de Walle G, Erb H, Perkins GA, Osterrieder N. The effect of siRNA treatment on experimental equine herpesvirus type 1 (EHV-1) infection in horses. Virus Res 2010 Feb;147(2):176-81.
                doi: 10.1016/j.virusres.2009.10.017pubmed: 19896512google scholar: lookup
              24. Fulton A, Peters ST, Perkins GA, Jarosinski KW, Damiani A, Brosnahan M, Buckles EL, Osterrieder N, Van de Walle GR. Effective treatment of respiratory alphaherpesvirus infection using RNA interference. PLoS One 2009;4(1):e4118.
                doi: 10.1371/journal.pone.0004118pubmed: 19122813google scholar: lookup
              25. Goodman LB, Loregian A, Perkins GA, Nugent J, Buckles EL, Mercorelli B, Kydd JH, Palù G, Smith KC, Osterrieder N, Davis-Poynter N. A point mutation in a herpesvirus polymerase determines neuropathogenicity. PLoS Pathog 2007 Nov;3(11):e160.
                doi: 10.1371/journal.ppat.0030160pubmed: 17997600google scholar: lookup
              26. Lewis MJ, Wagner B, Woof JM. The different effector function capabilities of the seven equine IgG subclasses have implications for vaccine strategies. Mol Immunol 2008 Feb;45(3):818-27.
                doi: 10.1016/j.molimm.2007.06.158pubmed: 17669496google scholar: lookup
              27. Jacks S, Giguère S, Crawford PC, Castleman WL. Experimental infection of neonatal foals with Rhodococcus equi triggers adult-like gamma interferon induction. Clin Vaccine Immunol 2007 Jun;14(6):669-77.
                doi: 10.1128/CVI.00042-07pubmed: 17409222google scholar: lookup
              28. Schmitz M, Neugebauer E, Full F, Conn KL. Cross-Species Analysis of Transcriptomic Response to Alpha-Herpesvirus Infection in Human, Bovine and Equine Cells. Int J Mol Sci 2026 Jan 27;27(3).
                doi: 10.3390/ijms27031261pubmed: 41683687google scholar: lookup
              29. Cooper CJ, Arroyo LG, Hammermueller JD, Botts MM, Pearl DL, Wootton SK, Lillie BN. Molecular prevalence of equine alphaherpesvirus-1 shedding in healthy broodmares in Ontario. Can J Vet Res 2026 Jan;90(1):16-24.
                pubmed: 41585008
              30. Tsujimura K, Bannai H, Kambayashi Y, Nemoto M, Ohta M. Detection of equid alphaherpesvirus 1 in serum samples collected from infected horses. J Vet Diagn Invest 2025 May;37(3):495-498.
                doi: 10.1177/10406387251323272pubmed: 40022421google scholar: lookup
              31. Pradhan SS, Balena V, Bera BC, Anand T, Khetmalis R, Madhwal A, Kandasamy S, Pavulraj S, Bernela M, Mor P, Tripathi BN, Virmani N. Multiple Gene Deletion Mutants of Equine Herpesvirus 1 Exhibit Strong Protective Efficacy Against Wild Virus Challenge in a Murine Model. Vaccines (Basel) 2025 Jan 8;13(1).
                doi: 10.3390/vaccines13010045pubmed: 39852824google scholar: lookup
              32. Mohamed E, Zarak I, Vereecke N, Theuns S, Laval K, Nauwynck H. Genomic analysis and replication kinetics of the closely related EHV-1 neuropathogenic 21P40 and abortigenic 97P70 strains. Vet Res 2025 Jan 13;56(1):12.
                doi: 10.1186/s13567-024-01434-3pubmed: 39806433google scholar: lookup
              33. Pusterla N, Lawton K, Barnum S, Ross K, Purcell K. Investigation of an Outbreak of Equine Herpesvirus-1 Myeloencephalopathy in a Population of Aged Working Equids. Viruses 2024 Dec 21;16(12).
                doi: 10.3390/v16121963pubmed: 39772269google scholar: lookup
              34. Nishimura F, Fukushi N, Sakai H, Fukushi H. Attenuation of the neuropathogenic equine herpesvirus type 1 strain Ab4p in hamsters by a single amino acid mutation (D752N) in viral DNA polymerase ORF30. J Vet Med Sci 2024 Dec 1;86(12):1273-1278.
                doi: 10.1292/jvms.24-0338pubmed: 39384384google scholar: lookup
              35. Giessler KS, Goehring LS, Jacob SI, Davis A, Esser MM, Lee Y, Zarski LM, Weber PSD, Hussey GS. Impact of the host immune response on the development of equine herpesvirus myeloencephalopathy in horses. J Gen Virol 2024 May;105(5).
                doi: 10.1099/jgv.0.001987pubmed: 38767608google scholar: lookup
              36. Eady NA, Holmes C, Schnabel C, Babasyan S, Wagner B. Equine herpesvirus type 1 (EHV-1) replication at the upper respiratory entry site is inhibited by neutralizing EHV-1-specific IgG1 and IgG4/7 mucosal antibodies. J Virol 2024 Jun 13;98(6):e0025024.
                doi: 10.1128/jvi.00250-24pubmed: 38742875google scholar: lookup
              37. Soboll-Hussey G, Dorman DC, Burgess BA, Goehring L, Gross P, Neinast C, Osterrieder K, Pusterla N, Lunn DP. Relationship between equine herpesvirus-1 viremia and abortion or equine herpesvirus myeloencephalopathy in domesticated horses: A systematic review. J Vet Intern Med 2024 May-Jun;38(3):1872-1891.
                doi: 10.1111/jvim.16948pubmed: 38069576google scholar: lookup
              38. Osterrieder K, Dorman DC, Burgess BA, Goehring LS, Gross P, Neinast C, Pusterla N, Hussey GS, Lunn DP. Vaccination for the prevention of equine herpesvirus-1 disease in domesticated horses: A systematic review and meta-analysis. J Vet Intern Med 2024 May-Jun;38(3):1858-1871.
                doi: 10.1111/jvim.16895pubmed: 37930113google scholar: lookup
              39. Khatibzadeh SM, Gold CB, Keggan AE, Perkins GA, Glaser AL, Dubovi EJ, Wagner B. West Nile virus-specific immunoglobulin isotype responses in vaccinated and infected horses. Am J Vet Res 2015 Jan;76(1):92-100.
                doi: 10.2460/ajvr.76.1.92pubmed: 25535666google scholar: lookup
              40. Keggan A, Freer H, Rollins A, Wagner B. Production of seven monoclonal equine immunoglobulins isotyped by multiplex analysis. Vet Immunol Immunopathol 2013 Jun 15;153(3-4):187-93.
                doi: 10.1016/j.vetimm.2013.02.010pubmed: 23541920google scholar: lookup
              Subscribe to our newsletter
              Join 99,727 horse owners like you who receive our email updates on horse health and nutrition.